Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
PODCAST | Product Development

Biotech in the New Year. Plus: Beyond Biosecure

Picks, perils and predictions for biopharma in 2025 — the latest BioCentury podcast

January 7, 2025 2:44 AM UTC

Can biotech break free of the macro factors that have buffeted the industry of late? On the first BioCentury This Week podcast of 2025, BioCentury’s editors offer their predictions for the New Year and — exploring the themes from Simone Fishburn’s latest Letter from the Editor — ask whether biotech can overcome the financing environment, policy concerns and geopolitical tension that have been hammering the industry to deliver on the meaningful strides companies have been taking to deliver innovations to patients.

Plus, Washington Editor Steve Usdin discusses what U.S. policymakers need to do now in the wake of a year’s worth of wrangling over the Biosecure Act, and Executive Editor Selina Koch breaks down readouts from Neumora Inc. (NASDAQ:NMRA) on its KOR antagonist navacaprant to treat major depressive disorder and  Axsome Therapeutics Inc. (NASDAQ:AXSM) for its AXS-05 to treat agitation in Alzheimer’s patients.

Purchase Reprint/Distribution Rights
Continue reading with a free trial.
Or Purchase This Article